1)Burch HB, Wartofsky L:Graves' ophthalmopathy:current concepts regarding pathogenesis and management. Endocr Rev 14:747-793, 1993
2)Tallstedt L, Lundell G, Torring O et al:Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 326:1733-1738, 1992
3)Bartalena L, Marcocci C, Bogazzi F et al:Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 338:73-78, 1998
4)Marcocci C, Bartalena L, Tanda ML et al:Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy:results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 86:3562-3567, 2001
5)渡邊奈津子・吉村 弘・國井 葉・他:バセドウ病患者において甲状腺機能正常(Eu)を目指した131I内用療法(RI)の長期予後.日本内分泌学会雑誌 20:279,2010
6)Sugino K, Ito K, Ozaki O et al:Postoperative changes in thyrotropin-binding inhibitory immunoglobulin level in patients with Graves' disease:is subtotal thyroidectomy a suitable therapeutic option for patients of childbearing age with Graves' disease ? World J Surg 23:727-731, 1999
7)Abe Y, Sato H, Noguchi M et al:Effect of subtotal thyroidectomy on natural history of ophthalmopathy in Graves' disease. World J Surg 22:714-717, 1998
8)Witte J, Goretzki PE, Dotzenrath C et al:Surgery for Graves' disease:total versus subtotal thyroidectomy-results of a prospective randomized trial. World J Surg 24:1303-1311, 2000
9)Kurihara H:Total thyroidectomy for the treatment of hyperthyroidism in patients with ophthalmopathy. Thyroid 12:265-267, 2002
10)Toyoda N, Yasuzawa-Amano S, Nomura E et al:Thyroid hormone activation in vascular smooth muscle cells is negatively regulated by glucocorticoid. Thyroid 19:755-763, 2009
11)Abraham P, Avenell A, Park CM et al:A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol 153:489-498, 2005